RxDoctor Payments Data

Chima Nwaukwa, MD

Interventional Cardiology · Beaumont, TXNPI 1477657807

Payments from drug & device makers

$118,313in general payments, 2019–2025

Across 442 payments — averaging $267.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$84K
  • Merck$26K
  • Boston Scientific$3K
  • Shockwave Medical, Inc$1K
  • Edwards Lifesciences$780
  • Abbott$581
  • plus $3K from 22 others

What the payments were for

  • Speaking & faculty fees$18,62053%
  • Travel & lodging$6,43318%
  • Food & beverage$9,74728%
  • Education$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$118,313 in reported general payments places this provider in the 85th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$236,004
Medicare patients
378
Services billed
2,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban349$393,193
XareltoRivaroxaban178$160,125
EntrestoSacubitril/Valsartan110$142,813
FarxigaDapagliflozin Propanediol84$76,358
VerquvoVericiguat44$37,868
JardianceEmpagliflozin29$34,024
BrilintaTicagrelor54$29,395
NexletolBempedoic Acid38$18,782
MultaqDronedarone Hcl16$16,725
Ranolazine ErRanolazine83$13,263
Repatha SureclickEvolocumab11$10,162
Icosapent Ethyl15$7,885
Dabigatran EtexilateDabigatran Etexilate Mesylate16$6,212
Metoprolol Succinate368$4,191
Atorvastatin Calcium358$3,352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$298$393,193349 claims
Johnson & JohnsonXarelto$279$160,125178 claims
NovartisEntresto$466$142,813110 claims
AstraZenecaFarxiga, Brilinta$296$105,752138 claims
MerckVerquvo$25,780$37,86844 claims
Boehringer IngelheimJardiance$68$34,02429 claims
Esperion Therapeutics, Inc.Nexletol$102$18,78238 claims
Sanofi-aventis U.S. LLCMultaq$123$16,72516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Beaumont

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →